News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2019

June 18, 2019
Kyowa Hakko Kirin Receives the Partial Change Approval of Romiplate® for Aplastic Anemia in Japan
June 17, 2019
Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Study of Brodalumab (KHK4827) in Patients with Axial Spondyloarthritis and Oral Presentation at EULAR
June 13, 2019
For a World with Better Health and Well-beings Kyowa Hakko Kirin Brand Content Mirai Port Launched
May 8, 2019
New window opensAnnouncement of Consolidated Financial Results Fiscal 2019 First Quarter
April 24, 2019
Notice Concerning Completion of Consolidated Subsidiary Share TransferPDF file:New window opens(223KB)
April 24, 2019
Kyowa Hakko Kirin Submits the Partial Change Approval Application of KHK7580 (evocalcet) in Japan
April 10, 2019
Result of Voluntary Early Retirement OfferPDF file:New window opens(222KB)
April 4, 2019
Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the USPDF file:New window opens(146KB)
March 29, 2019
Matters concerning controlling shareholdersPDF file:New window opens(121KB)
March 25, 2019
Kyowa Hakko Kirin Enters New Development and Commercialisation Agreements with AstraZeneca for All Benralizumab Indications beyond COPD and Asthma in Asia Inclusive of Japan
March 20, 2019
Notice Regarding Allotment of Share Acquisition Rights (Share Remuneration-type Stock Options)PDF file:New window opens(104KB)
March 18, 2019
Kyowa Kirin Asia Pacific Announces Establishment of Subsidiary in Australia
March 1, 2019
Kyowa Kirin Announces Refiling of Istradefylline (KW-6002)'s New Drug Application in the US
February 19, 2019
Notice Regarding Partial Amendments to the Articles of IncorporationPDF file:New window opens(237KB)
February 19, 2019
Notice Regarding Share Acquisition Rights for Share Remuneration-type Stock OptionsPDF file:New window opens(237KB)
February 19, 2019
Notice Regarding Change in Exercise Condition of Share Remuneration-type Stock OptionsPDF file:New window opens(313KB)
February 15, 2019
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)PDF file:New window opens(237KB)
February 6, 2019
Notice regarding the Result of Repurchase of Own Shares through Off-Auction Own Share Repurchase Trading (ToSTNeT-3) and Completion of Repurchase of Own SharesPDF file:New window opens(112KB)
February 6, 2019
Kyowa Hakko Kirin Initiated Phase 2 Clinical Study of Tenapanor (KHK7791) for Hyperphosphataemia Patients on Hemodialysis in Japan
February 5, 2019
Notice Concerning Share Transfer Associated with Change in a Consolidated Company and (Expected) Gain on TransferPDF file:New window opens(309KB)
February 5, 2019
New window opensAnnouncement of Consolidated Financial Results Fiscal 2018
February 5, 2019
Kyowa Hakko Kirin Announces Changes in the Executive DirectorsPDF file:New window opens(104KB)
February 5, 2019
Offer of Voluntary Early RetirementPDF file:New window opens(96KB)
February 5, 2019
Notice regarding Repurchase of Own Shares, Purchase of Own Shares through Off-Auction Own Share Repurchase Trading (ToSTNeT-3), and Cancellation of Treasury Shares
(Repurchase of Own Shares under the Provisions of Articles of Incorporation pursuant to the Provisions of Article 165, Paragraph 2 of the Companies Act and Purchase of Own Shares through Off-Auction Own Share Repurchase Trading (ToSTNeT-3), and Cancellation of Treasury Shares pursuant to the Provisions of Article 178 of the Companies Act)
PDF file:New window opens(123KB)
February 5, 2019
Kyowa Hakko Kirin Announces Changes in Global Management StructurePDF file:New window opens(159KB)
February 5, 2019
Kyowa Hakko Kirin Announces Organizational ChangesPDF file:New window opens(150KB)
February 5, 2019
Kyowa Kirin Announces CI Logotype Change
February 5, 2019
Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson's Disease in Japan
January 7, 2019
Kyowa Hakko Kirin Submits Application for Approval of Burosumab for FGF23-related Hypophosphatemic Rickets and Osteomalacia in Japan

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top